Performance. Defined.

InVitria Blog | Cell Culture and Biotech Manufacturing Insights

Expansion of Adherent HEK293t Cells in Flasks in Chemically Defined Cell Culture Media

Posted By Attie Pennybaker on 11/18/19 4:34 PM

Workflow Summary:

New call-to-actionCombine supplements of OptiPEAK HEK293t media. Generate stock solutions and prepare reagents. Adapt HEK293t cells in log phase growth from serum to OptiPEAK HEK293t chemically defined, serum free media. Subculture HEK293t cells every 2-3 days in T-75 flasks, calculating doubling time and population doublings to determine cumulative expansion results.

Read More

Stabilizing Virus with Albumin to Improve Yield

Posted By Randy Alfano Ph.D. on 10/22/19 11:02 AM

Workflow Summary:

Expand virus-producing cells to desired confluency. RemoveNew call-to-action growth medium and add the desired virus to be expanded (virus or plasmid DNA). Add Exbumin (Product Number: 777HSA097S) to the expression media and allow virus to propagate. Harvest culture and determine virus titer by preferred method.

Here, a general protocol is described for the addition of recombinant albumin, in the form of the product Exbumin, to virus production systems to stabilize infectious particles and thereby maximize viral yield.

 

Read More

Recombinant Human Leukemia Inhibitory Factor for the Enhanced Expansion of Neural Stem Cells

Posted By Marcus Curl on 6/27/19 8:29 PM

rhLIF App Note #1 Download CTA ButtonWorkflow Summary:

Applying neural stem cells (NSC) as a cell therapy has created new hope for the treatment of various neural degenerative diseases as well as the reversal of neural damage once thought to be irreparable. Currently, clinical trials are being performed to evaluate NSC for the treatment of stroke, Parkinson’s disease, spinal cord injuries, and many other indications [1]. As new potential applications emerge and new clinical trials begin, the need for scalable and safe sources of the foundational cell culture materials becomes essential to the future of this technology. The ability to quickly and reliably expand neural NSCs in culture has therefore been essential to the exploration of these novel, cell-based therapeutic approaches. The goal of this application note is to provide step-by-step instructions for using InVitria’s recombinant hLIF in the efficient, safe, and scalable expansion of NSC in culture.

Read More

Reconstitution of Cellastim S for Cell-Culture Applications

Posted By Marcus Curl on 6/18/19 8:53 AM

Workflow Summary:Cellastim S Reconstitution Application Note #2 Download CTA Button

Human serum albumin (HSA) has been identified as a powerful tool for the expansion of many cell types in vitro [1]. HSA is a multifaceted protein capable of binding many different types of molecules [2]. HSA therefore plays diverse roles in cell biology, acting as an antioxidant to improve health of cells by binding to reactive oxygen species, as an energy-delivery system by chaperoning fatty acids in the bloodstream, and as a mediator for solubilization and stabilization of metal ions required for cellular processes [2,3]. These functions make HSA supplementation of cell culture media an integral step in facilitating cell growth and expansion in vitro, especially when removing serum or blood-derived proteins for use in clinical manufacturing. Using Cellastim S as a recombinant and scalable source of albumin in cell culture is an enabling tool for large-scale manufacture of cell-based and gene therapies. It is the goal of this app note to provide a step-by-step overview for preparing Cellastim S for use as a stock liquid solution for in vitro cell culture applications.

Read More

Using Recombinant Transferrin in the Expansion of Hematopoietic Stem Cells

Posted By Marcus Curl on 5/29/19 1:00 PM

InVitira Optiferrin App Note 1 Download CTAIntroduction:

A growing number of clinical cases have provided strong proof of concept that hematopoietic stem-cell (HSC) therapies are potential treatments of blood cancers and many other debilitating diseases that were once thought to be incurable [1]. A critical tool to enable development of these therapies is expansion of HSCs in vitro [2]. However, supplementation of HSC growth media with serum-derived media supplements such as those included in xeno-free media and other animal-derived components can introduce adventitious pathogenic agents, create variability when cell expansion processes are scaled up for manufacturing, and can also present the risk of a supply chain interruption for clinical product manufacturing.

Read More